Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms

Journal of Autoimmunity

Volumn 52, Issue , 2014, Pages 90-100

  Berrih Aknin, Sonia ^a,b,c,d   Le Panse, Rozen ^a,b,c,d  

^a Sorbonne Université   (France)

^b University of Versailles Saint Quentin en Yvelines   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d AIM   (France)

Author keywords

Genetics; Germinal centers; IL 17; Inflammation; MiRNA; Treg cells

Indexed keywords

CHEMOKINE; CHOLINERGIC RECEPTOR ANTIBODY; MICRORNA; SEX HORMONE; TUMOR NECROSIS FACTOR ALPHA; INTERFERON; LRP4 ANTIBODY; MUSK ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; CHOLINERGIC RECEPTOR; LOW DENSITY LIPOPROTEIN; MUSK PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ANGIOGENESIS; CLINICAL FEATURE; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GERMINAL CENTER; HUMAN; HYPERPLASIA; IMMUNE DYSREGULATION; MYASTHENIA GRAVIS; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROLOGY; T LYMPHOCYTE; TH17 CELL; THYMECTOMY; THYMIC FOLLICULAR HYPERPLASIA; THYMOMA; THYMUS; THYMUS DISEASE; UPREGULATION; VIRUS INFECTION; FOLLICULAR HYPERPLASIA; HYPOTHESIS; NONHUMAN; RISK FACTOR; ANIMAL; COMPLICATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TH1 CELL; THYMUS NEOPLASMS;

ANIMALS; AUTOANTIBODIES; HUMANS; HYPERPLASIA; LIPOPROTEINS, LDL; MICRORNAS; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; TH1 CELLS; TH17 CELLS; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS; VIRUS DISEASES;

EID: 84904308431     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.12.011     Document Type: Review

References (142)

1. Carr A.S., Cardwell C.R., McCarron P.O., McConville J. Asystematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010, 10:46.
2. Somnier F.E., Keiding N., Paulson O.B. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 1991, 48:733-739.
3. Pestronk A., Drachman D.B., Self S.G. Measurement of junctional acetylcholine receptors in myasthenia gravis: clinical correlates. Muscle Nerve 1985, 8:245-251.
4. Limburg P.C., The T.H., Hummel-Tappel E., Oosterhuis H.J. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. JNeurol Sci 1983, 58:357-370.
5. Nakano S., Engel A.G. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993, 43:1167-1172.
6. Le Panse R., Berrih-Aknin S. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation. Curr Opin Neurol 2013, 26:569-576.
7. Tuzun E., Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev 2013, 12:904-911.
8. Verschuuren J.J., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12:918-923.
9. Eymard B., Vernet-der Garabedian B., Berrih-Aknin S., Pannier C., Bach J.F., Morel E. Anti-acetylcholine receptor antibodies in neonatal myasthenia gravis: heterogeneity and pathogenic significance. JAutoimmun 1991, 4:185-195.
10. Guyon T., Levasseur P., Truffault F., Cottin C., Gaud C., Berrih-Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. JClin Invest 1994, 94:16-24.
11. Guyon T., Wakkach A., Poea S., Mouly V., Klingel-Schmitt I., Levasseur P., et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. JClin Invest 1998, 102:249-263.
12. Kida K., Hayashi M., Yamada I., Matsuda H., Yoshinaga J., Takami S., et al. Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized types. Ann Neurol 1987, 21:274-278.
13. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
14. Berrih-Aknin S., Ruhlmann N., Bismuth J., Cizeron-Clairac G., Zelman E., Shachar I., et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 2009, 66:521-531.
15. Eymard B., Berrih-Aknin S. Role of the thymus in the physiopathology of myasthenia. Rev Neurol (Paris) 1995, 151:6-15.
16. Thorlacius S., Aarli J.A., Riise T., Matre R., Johnsen H.J. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989, 80:290-295.
17. Romi F., Skeie G.O., Aarli J.A., Gilhus N.E. Muscle autoantibodies in subgroups of myasthenia gravis patients. JNeurol 2000, 247:369-375.
18. Romi F., Aarli J.A., Gilhus N.E. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007, 14:617-620.
19. Aragones J.M., Bolibar I., Bonfill X., Bufill E., Mummany A., Alonso F., et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003, 60:1024-1026.
20. Casetta I., Groppo E., De Gennaro R., Cesnik E., Piccolo L., Volpato S., et al. Myasthenia gravis: a changing pattern of incidence. JNeurol 2010, 257:2015-2019.
21. DeChiara T.M., Bowen D.C., Valenzuela D.M., Simmons M.V., Poueymirou W.T., Thomas S., et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation invivo. Cell 1996, 85:501-512.
22. Lin W., Burgess R.W., Dominguez B., Pfaff S.L., Sanes J.R., Lee K.F. Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse. Nature 2001, 410:1057-1064.
23. Lavrnic D., Losen M., Vujic A., De Baets M., Hajdukovic L.J., Stojanovic V., et al. The features of myasthenia gravis with autoantibodies to MuSK. JNeurol Neurosurg Psychiatr 2005, 76:1099-1102.
24. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
25. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
26. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
27. Punga A.R., Lin S., Oliveri F., Meinen S., Ruegg M.A. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol 2011, 230:207-217.
28. Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
29. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
30. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
31. Zisimopoulou P., Evangelakou P., Tzartos J., Lazaridis K., Belimezi M., Zouvelou V., et al. A Comprehensive Analysis of the Epidemiology and Clinical Characteristics of Anti-LRP4 in Myasthenia Gravis. J Autoimmun 2014, 52:139-145.
32. Jacob S., Viegas S., Leite M.I., Webster R., Cossins J., Kennett R., et al. Presence andpathogenic relevance of antibodies to clustered acetylcholine receptorinocular and generalized myasthenia gravis. Arch Neurol 2012, 69:994-1001.
33. Cossins J., Belaya K., Zoltowska K., Koneczny I., Maxwell S., Jacobson L., et al. The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 2012, 1275:123-128.
34. Derbinski J., Schulte A., Kyewski B., Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001, 2:1032-1039.
35. Suniara R.K., Jenkinson E.J., Owen J.J. An essential role for thymic mesenchyme in early T cell development. JExp Med 2000, 191:1051-1056.
36. Le Panse R., Berrih-Aknin S. Thymic myoid cells protect thymocytes from apoptosis and modulate their differentiation: implication of the ERK and Akt signaling pathways. Cell Death Differ 2005, 12:463-472.
37. Berrih-Aknin S., Morel E., Raimond F., Safar D., Gaud C., Binet J.P., et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann N Y Acad Sci 1987, 505:50-70.
38. Suster S., Moran C.A. Thymoma classification: current status and future trends. Am J Clin Pathol 2006, 125:542-554.
39. Filosso P.L., Galassi C., Ruffini E., Margaritora S., Bertolaccini L., Casadio C., et al. Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study. Eur J Cardiothorac Surg 2013, 44:219-224.
40. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Strobel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884.
41. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003, 132:128-136.
42. Cufi P., Soussan P., Truffault F., Fetouchi R., Robinet M., Fadel E., et al. Thymoma-associated myasthenia gravis: on the search for a pathogen signature. JAutoimmun 2014, 52:29-35.
43. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
44. Berrih S., Morel E., Gaud C., Raimond F., Le Brigand H., Bach J.F. Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology 1984, 34:66-71.
45. Leprince C., Cohen-Kaminsky S., Berrih-Aknin S., Vernet-Der Garabedian B., Treton D., Galanaud P., et al. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. JImmunol 1990, 145:2115-2122.
46. Lisak R.P., Levinson A.I., Zweiman B., Kornstein M.J. Antibodies to acetylcholine receptor and tetanus toxoid: invitro synthesis by thymic lymphocytes. JImmunol 1986, 137:1221-1225.
47. Safar D., Berrih-Aknin S., Morel E. Invitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: correlations with thymic histology and thymic epithelial-cell interactions. JClin Immunol 1987, 7:225-234.
48. Fujii Y., Hashimoto J., Monden Y., Ito T., Nakahara K., Kawashima Y. Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis. JImmunol 1986, 136:887-891.
49. Yoshikawa H., Satoh K., Yasukawa Y., Yamada M. Analysis of immunoglobulin secretion by lymph organs with myasthenia gravis. Acta Neurol Scand 2001, 103:53-58.
50. Schonbeck S., Padberg F., Hohlfeld R., Wekerle H. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. JClin Invest 1992, 90:245-250.
51. Aissaoui A., Klingel-Schmitt I., Couderc J., Chateau D., Romagne F., Jambou F., et al. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol 1999, 46:559-567.
52. Meraouna A., Cizeron-Clairac G., Panse R.L., Bismuth J., Truffault F., Tallaksen C., et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006, 108:432-440.
53. Weiss J.M., Cufi P., Bismuth J., Eymard B., Fadel E., Berrih-Aknin S., et al. SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus ofautoimmune myasthenia gravis patients. Immunobiology 2013, 218:373-381.
54. Le Panse R., Bismuth J., Cizeron-Clairac G., Weiss J.M., Cufi P., Dartevelle P., et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010, 43:401-412.
55. Weiss J.M., Cufi P., Le Panse R., Berrih-Aknin S. The thymus in autoimmune Myasthenia gravis: paradigm for a tertiary lymphoid organ. Rev Neurol (Paris) 2013, 169:640-649.
56. Luther S.A., Lopez T., Bai W., Hanahan D., Cyster J.G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000, 12:471-481.
57. Drayton D.L., Ying X., Lee J., Lesslauer W., Ruddle N.H. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. JExp Med 2003, 197:1153-1163.
58. Le Panse R., Cizeron-Clairac G., Bismuth J., Berrih-Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia. JImmunol 2006, 177:7868-7879.
59. Legler D.F., Loetscher M., Roos R.S., Clark-Lewis I., Baggiolini M., Moser B. Bcell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. JExp Med 1998, 187:655-660.
60. Saito R., Onodera H., Tago H., Suzuki Y., Shimizu M., Matsumura Y., et al. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients. JNeuroimmunol 2005, 170:172-178.
61. Luo C., Li Y., Liu W., Feng H., Wang H., Huang X., et al. Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis. JNeuroimmunol 2013, 256:55-61.
62. Cordiglieri C., Marolda R., Franzi S., Cappelletti C., Giardina C., Motta T., et al. Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. JAutoimmun 2014, 52:74-89.
63. Poea-Guyon S., Christadoss P., Le Panse R., Guyon T., De Baets M., Wakkach A., et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. JImmunol 2005, 174:5941-5949.
64. Tzartos S.J., Lindstrom J.M. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A 1980, 77:755-759.
65. Moulian N., Bidault J., Planche C., Berrih-Aknin S. Two signaling pathways can increase fas expression in human thymocytes. Blood 1998, 92:1297-1307.
66. Moulian N., Bidault J., Truffault F., Yamamoto A.M., Levasseur P., Berrih-Aknin S. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood 1997, 89:3287-3295.
67. Cohen-Kaminsky S., Gaud C., Morel E., Berrih-Aknin S. High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes from patients with myasthenia gravis: correlations with clinical parameters. JAutoimmun 1989, 2:241-258.
68. Link J., Navikas V., Yu M., Fredrikson S., Osterman P.O., Link H. Augmented interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in blood mononuclear cells in myasthenia gravis. JNeuroimmunol 1994, 51:185-192.
69. Feferman T., Maiti P.K., Berrih-Aknin S., Bismuth J., Bidault J., Fuchs S., et al. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. JImmunol 2005, 174:5324-5331.
70. Gradolatto A., Nazzal D., Truffault F., Bismuth J., Fadel E., Foti M., et al. Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-α. JAutoimmun 2014, 52:53-63.
71. Hori S., Takahashi T., Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003, 81:331-371.
72. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010, 10:849-859.
73. Balandina A., Lecart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
74. Matsui N., Nakane S., Saito F., Ohigashi I., Nakagawa Y., Kurobe H., et al. Undiminished regulatory T cells in the thymus of patients with myasthenia gravis. Neurology 2010, 74:816-820.
75. Battaglia A., Di Schino C., Fattorossi A., Scambia G., Evoli A. Circulating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: a flow cytometry study. JBiol Regul Homeost Agents 2005, 19:54-62.
76. Thiruppathi M., Rowin J., Li Jiang Q., Sheng J.R., Prabhakar B.S., Meriggioli M.N. Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci 2012, 1274:68-76.
77. Zhang Y., Wang H.B., Chi L.J., Wang W.Z. The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis. Immunol Lett 2009, 122:52-57.
78. Luther C., Adamopoulou E., Stoeckle C., Brucklacher-Waldert V., Rosenkranz D., Stoltze L., et al. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. JImmunol 2009, 183:841-848.
79. Gradolatto A., Nazzal D., Foti M., Bismuth J., Truffault F., Panse R.L., et al. Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17. Ann N Y Acad Sci 2012, 1274:40-47.
80. Roche J.C., Capablo J.L., Larrad L., Gervas-Arruga J., Ara J.R., Sanchez A., et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011, 44:278-280.
81. Masuda M., Matsumoto M., Tanaka S., Nakajima K., Yamada N., Ido N., et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. JNeuroimmunol 2010, 225:123-131.
82. Wang Z., Wang W., Chen Y., Wei D. Thelper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol 2012, 76:54-61.
83. Aime C., Cohen-Kaminsky S., Berrih-Aknin S. Invitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis. JClin Immunol 1991, 11:268-278.
84. Cohen-Kaminsky S., Devergne O., Delattre R.M., Klingel-Schmitt I., Emilie D., Galanaud P., et al. Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur Cytokine Netw 1993, 4:121-132.
85. Spillane J., Hayward M., Hirsch N.P., Taylor C., Kullmann D.M., Howard R.S. Thymectomy: role in the treatment of myasthenia gravis. JNeurol 2013, 260:1798-1801.
86. Budde J.M., Morris C.D., Gal A.A., Mansour K.A., Miller J.I. Predictors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg 2001, 72:197-202.
87. Nieto I.P., Robledo J.P., Pajuelo M.C., Montes J.A., Giron J.G., Alonso J.G., et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg 1999, 67:1568-1571.
88. Okumura M., Ohta M., Takeuchi Y., Shiono H., Inoue M., Fukuhara K., et al. The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer. JThorac Cardiovasc Surg 2003, 126:1922-1928.
89. Newsom-Davis J., Cutter G., Wolfe G.I., Kaminski H.J., Jaretzki A., Minisman G., et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci 2008, 1132:344-347.
90. Ramanujam R., Pirskanen R., Ramanujam S., Hammarstrom L. Utilizing twins concordance rates to infer the predisposition to myasthenia gravis. Twin Res Hum Genet 2011, 14:129-136.
91. Vandiedonck C., Giraud M., Garchon H.J. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. JAutoimmun 2005, 25(Suppl):6-11.
92. Giraud M., Vandiedonck C., Garchon H.J. Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci 2008, 1132:180-192.
93. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8:475-490.
94. Avidan N., Le Panse R., Berrih-Aknin S., Miller A. Genetic basis of autoimmune myasthenia gravis - A comprehensive review. JAutoimmun 2014, 52:146-153.
95. Huang D.R., Pirskanen R., Matell G., Lefvert A.K. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. JNeuroimmunol 1999, 94:165-171.
96. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Panse R.L. Etiology of myasthenia gravis: Innate immunity signature in pathological thymus. Autoimmun Rev 2013, 12:863-874.
97. Landoure G., Knight M.A., Stanescu H., Taye A.A., Shi Y., Diallo O., et al. Acandidate gene for autoimmune myasthenia gravis. Neurology 2012, 79:342-347.
98. Gregersen P.K., Kosoy R., Lee A.T., Lamb J., Sussman J., McKee D., et al. Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 2012, 72:927-935.
99. Hystad M.E., Myklebust J.H., Bo T.H., Sivertsen E.A., Rian E., Forfang L., et al. Characterization of early stages of human B cell development by gene expression profiling. JImmunol 2007, 179:3662-3671.
100. Bowes J., Orozco G., Flynn E., Ho P., Brier R., Marzo-Ortega H., et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011, 70:1641-1644.
101. Zhang J., Chen Y., Shao Y., Wu Q., Guan M., Zhang W., et al. Identification of TNIP1 polymorphisms by high resolution melting analysis with unlabelled probe: association with systemic lupus erythematosus. Autoimmune Dis 2012, 2012. In press.
102. Boone D.L., Turer E.E., Lee E.G., Ahmad R.C., Wheeler M.T., Tsui C., et al. The ubiquitin-modifying enzyme A20 is required for termination of toll-like receptor responses. Nat Immunol 2004, 5:1052-1060.
103. Nanda S.K., Venigalla R.K., Ordureau A., Patterson-Kane J.C., Powell D.W., Toth R., et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. JExp Med 2011, 208:1215-1228.
104. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9:102-114.
105. Tang Y., Luo X., Cui H., Ni X., Yuan M., Guo Y., et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009, 60:1065-1075.
106. Alsaleh G., Suffert G., Semaan N., Juncker T., Frenzel L., Gottenberg J.E., et al. Bruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. JImmunol 2009, 182:5088-5097.
107. Lu T.X., Munitz A., Rothenberg M.E. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. JImmunol 2009, 182:4994-5002.
108. Baltimore D., Boldin M.P., O'Connell R.M., Rao D.S., Taganov K.D. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008, 9:839-845.
109. Cheng Z., Qiu S., Jiang L., Zhang A., Bao W., Liu P., et al. MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1. JClin Immunol 2013, 33:567-576.
110. Sun W., Adams R.N., Miagkov A., Lu Y., Juon H.S., Drachman D.B. Specific immunotherapy of experimental myasthenia gravis invitro and invivo: the guided missile strategy. JNeuroimmunol 2012, 251:25-32.
111. Goren Y., Kushnir M., Zafrir B., Tabak S., Lewis B.S., Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012, 14:147-154.
112. Jiang L., Cheng Z., Qiu S., Que Z., Bao W., Jiang C., et al. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. Int Immunopharmacol 2012, 14:217-223.
113. Gandhi R., Healy B., Gholipour T., Egorova S., Musallam A., Hussain M.S., et al. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013, 73:729-740.
114. Wang S., Tang Y., Cui H., Zhao X., Luo X., Pan W., et al. Let-7/miR-98 regulate Fas and Fas-mediated apoptosis. Genes Immun 2011, 12:149-154.
115. Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev 2012, 11:A479-A485.
116. Cai Y., Zhou J., Webb D.C. Estrogen stimulates Th2 cytokine production and regulates the compartmentalisation of eosinophils during allergen challenge in a mouse model of asthma. Int Arch Allergy Immunol 2012, 158:252-260.
117. Straub R.H. The complex role of estrogens in inflammation. Endocr Rev 2007, 28:521-574.
118. Shim G.J., Kis L.L., Warner M., Gustafsson J.A. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci U S A 2004, 101:1720-1724.
119. Staples J.E., Gasiewicz T.A., Fiore N.C., Lubahn D.B., Korach K.S., Silverstone A.E. Estrogen receptor alpha is necessary in thymic development and estradiol-induced thymic alterations. JImmunol 1999, 163:4168-4174.
120. Hirahara H., Ogawa M., Kimura M., Iiai T., Tsuchida M., Hanawa H., et al. Glucocorticoid independence of acute thymic involution induced by lymphotoxin and estrogen. Cell Immunol 1994, 153:401-411.
121. Tai P., Wang J., Jin H., Song X., Yan J., Kang Y., et al. Induction of regulatory T cells by physiological level estrogen. JCell Physiol 2008, 214:456-464.
122. Vijayan N., Vijayan V.K., Dreyfus P.M. Acetylcholinesterase activity and menstrual remissions in myasthenia gravis. JNeurol Neurosurg Psychiatr 1977, 40:1060-1065.
123. Ramirez C., de Seze J., Delrieu O., Stojkovic T., Delalande S., Fourrier F., et al. Myasthenia gravis and pregnancy: clinical course and management of delivery and the postpartum phase. Rev Neurol (Paris) 2006, 162:330-338.
124. Nancy P., Berrih-Aknin S. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology 2005, 146:2345-2353.
125. Leker R.R., Karni A., Brenner T., Weidenfeld J., Abramsky O. Effects of sex hormones on experimental autoimmune myasthenia gravis. Eur J Neurol 2000, 7:203-206.
126. Delpy L., Douin-Echinard V., Garidou L., Bruand C., Saoudi A., Guery J.C. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. JImmunol 2005, 175:5050-5057.
127. Savino W. The thymus is a common target organ in infectious diseases. PLoS Pathog 2006, 2:e62.
128. Cavalcante P., Barberis M., Cannone M., Baggi F., Antozzi C., Maggi L., et al. Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology 2010, 74:1118-1126.
129. Leis A.A., Szatmary G., Ross M.A., Stokic D.S. West nile virus infection and myasthenia gravis. Muscle Nerve 2014, 49:26-29.
130. Cizeron-Clairac G., Le Panse R., Frenkian-Cuvelier M., Meraouna A., Truffault F., Bismuth J., et al. Thymus and Myasthenia Gravis: what can we learn from DNA microarrays?. JNeuroimmunol 2008, 201-202:57-63.
131. Bernasconi P., Barberis M., Baggi F., Passerini L., Cannone M., Arnoldi E., et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005, 167:129-139.
132. Cufi P., Dragin N., Weiss J.M., Martinez-Martinez P., De Baets M.H., Roussin R., et al. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2013, 73:281-293.
133. Cavalcante P., Serafini B., Rosicarelli B., Maggi L., Barberis M., Antozzi C., et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010, 67:726-738.
134. Iwakiri D., Zhou L., Samanta M., Matsumoto M., Ebihara T., Seya T., et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. JExp Med 2009, 206:2091-2099.
135. Csuka D., Banati M., Rozsa C., Fust G., Illes Z. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012, 19:842-846.
136. Wang Y.Z., Yan M., Tian F.F., Zhang J.M., Liu Q., Yang H., et al. Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis. Inflammation 2013, 36:121-130.
137. Piccolo G., Franciotta D., Versino M., Alfonsi E., Lombardi M., Poma G. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment. JNeurol Neurosurg Psychiatr 1996, 60:348.
138. Mase G., Zorzon M., Biasutti E., Vitrani B., Cazzato G., Urban F., et al. Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis. JNeurol Neurosurg Psychiatr 1996, 60:348-349.
139. Dionisiotis J., Zoukos Y., Thomaides T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment. JNeurol Neurosurg Psychiatr 2004, 75:1079.
140. Batocchi A.P., Evoli A., Servidei S., Palmisani M.T., Apollo F., Tonali P. Myasthenia gravis during interferon alfa therapy. Neurology 1995, 45:382-383.
141. Meloni A., Furcas M., Cetani F., Marcocci C., Falorni A., Perniola R., et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. JClin Endocrinol Metab 2008, 93:4389-4397.
142. Cufi P., Dragin N., Ruhlmann N., Weiss J.M., Fadel E., Serraf A., et al. Central role of interferon-beta in thymic events leading to myasthenia gravis. JAutoimmun 2014, 52:44-52.